Identification and quantification of concentration-dependent biomarkers in MCF-7/BOS cells exposed to 17β-estradiol by 2-D DIGE and label-free proteomics

Journal of Proteomics
Mike CollodoroMarie-Claire De Pauw-Gillet

Abstract

This paper reports the identification of biomarkers resulting from the exposure of MCF-7/BOS cells to 17β-estradiol (E(2)). The biomarkers were identified using 2 independent and complementary techniques, 2-D DIGE/MALDI-TOF peptide mass fingerprint, and 2-D UPLC-ESI MS/MS. They were identified from the cytosolic fractions of cells treated for 24h with mitogenic concentrations of 1, 30 and 500 pM of 17β-estradiol. Five biomarkers were up-regulated proteins, namely HSP 74, EF2, FKBP4, EF1 and GDIB and one was a down-regulated protein, namely K2C8. Three of these proteins, EF2, FKBP4 and K2C8 are implicated in a network centered on the estrogen receptors ESR1 and ESR2 as well as on AKT1. After the discovery phase, three biomarkers were selected to test the presence of estrogens using selected reaction monitoring (SRM). They were monitored using SRM after incubation of MCF-7/BOS in the presence of E(2) for confirmation or selected xenoestrogens. Daidzein, coumestrol and enterolactone induced an up-regulation of EF2 and FKPB4 proteins, while tamoxifen and resveratrol induced a down-regulation. The exposure of all phytoestrogens induced the down-regulation of K2C8. These markers form a preliminary molecular signature that can be used...Continue Reading

References

Nov 26, 1990·FEBS Letters·L P OvchinnikovB Hardesty
Oct 1, 1995·Environmental Health Perspectives·A M SotoF O Serrano
May 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T TedoneS J Reshkin
Jun 25, 1998·Electrophoresis·D FenyöB T Chait
May 20, 1999·Toxicological Sciences : an Official Journal of the Society of Toxicology·J LeglerB van der Burg
May 26, 2001·Biochemical and Biophysical Research Communications·P KumarT Ratajczak
Oct 22, 2002·Environmental Science & Technology·Juliette LeglerBart Van der Burg
Feb 21, 2004·BMJ : British Medical Journal·Richard M Sharpe, D Stewart Irvine
May 20, 2004·Molecular and Cellular Endocrinology·Yatrik M ShahBrian G Rowan
May 12, 2005·Domestic Animal Endocrinology·Ulf Magnusson
May 11, 2006·Environmental Science & Technology·B Rey DeCastroAna M Soto
Aug 24, 2007·Applied Microbiology and Biotechnology·Matthias BerthJörg Bernhardt
Apr 19, 2008·Proteome Science·Gabriel D MazzucchelliEdwin De Pauw
Jul 16, 2008·Reproductive Toxicology·Alberto MantovaniMaurizio Clementi
Oct 23, 2008·Nucleic Acids Research·Lars J JensenChristian von Mering
Jan 27, 2009·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Ramiro DipHanspeter Naegeli
Aug 12, 2009·Molecular & Cellular Proteomics : MCP·Zhuo ShenBai-Chen Wang
Sep 26, 2009·Journal of Proteome Research·Jean-Paul LasserreTorsten Bohn
Jan 5, 2010·Atmospheric Environment·Ruthann A Rudel, Laura J Perovich

❮ Previous
Next ❯

Citations

Dec 20, 2015·Environmental Science & Technology·Henrik KjeldalJeppe Nielsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.